# Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

> **NCT04329325** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Philadelphia Chromosome-Positive

## Interventions

- **BIOLOGICAL:** Blinatumomab
- **DRUG:** dasatinib
- **DRUG:** dexamethasone
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT04329325
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-30
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329325, "Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04329325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*